EP4587025A1 — Treating hiv with cabotegravir and rilpivirine in pediatric patients
Assigned to Viiv Healthcare Uk No3 Ltd · Expires 2025-07-23 · 1y expired
What this patent protects
The disclosure provides a method of treating HIV infection in a human pediatric patient by the administration of cabotegravir or a pharmaceutically acceptable salt thereof, in combination with rilpivirine or a pharmaceutically acceptable salt thereof.
USPTO Abstract
The disclosure provides a method of treating HIV infection in a human pediatric patient by the administration of cabotegravir or a pharmaceutically acceptable salt thereof, in combination with rilpivirine or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.